Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates
2014; Lippincott Williams & Wilkins; Volume: 32; Issue: 18 Linguagem: Inglês
10.1200/jco.2013.52.4785
ISSN1527-7755
AutoresToni K. Choueiri, Susanna Jacobus, Joaquim Bellmunt, Angela Qu, Leonard J. Appleman, Christopher Tretter, Glenn J. Bubley, Edward C. Stack, Sabina Signoretti, Meghara Walsh, Graeme S. Steele, Michelle S. Hirsch, Christopher J. Sweeney, Mary-Ellen Taplin, Adam S. Kibel, Katherine M. Krajewski, Philip W. Kantoff, Robert W. Ross, Jonathan E. Rosenberg,
Tópico(s)Viral-associated cancers and disorders
ResumoIn advanced urothelial cancer, treatment with dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) results in a high response rate, less toxicity, and few dosing delays. We explored the efficacy and safety of neoadjuvant ddMVAC with pegfilgrastim support in muscle-invasive urothelial cancer (MIUC).
Referência(s)